David T Huang1, Derek C Angus2, John A Kellum2, Nathan A Pugh3, Lisa A Weissfeld4, Joachim Struck5, Russell L Delude2, Matthew R Rosengart6, Donald M Yealy7. 1. Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Laboratory, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA; Departments of Critical Care Medicine, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA; Emergency Medicine, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA. Electronic address: huangdt@ccm.upmc.edu. 2. Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Laboratory, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA; Departments of Critical Care Medicine, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA. 3. Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA. 4. Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Laboratory, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA; Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA. 5. Research Department, BRAHMS AG, Biotechnology Centre, Hennigsdorf, Germany. 6. Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Laboratory, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA; Departments of Critical Care Medicine, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA; Surgery, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA. 7. Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Laboratory, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA; Emergency Medicine, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA.
Abstract
BACKGROUND: Midregional proadrenomedullin (MR-proADM) is a potential prognostic biomarker in patients with community-acquired pneumonia (CAP). Previous work has been hampered by sample size and illness spectrum limits. We sought to describe the pattern of MR-proADM in a broad CAP cohort, confirm its prognostic role, and compare its performance to procalcitonin, a novel biomarker of infection. METHODS: We conducted a multicenter prospective cohort study in 28 community and teaching EDs. Patients with a clinical and radiographic diagnosis of CAP were enrolled. We stratified MR-proADM levels a priori into quartiles and quantified severity of illness using the pneumonia severity index (PSI); and confusion (abbreviated mental test score of <or= 8), urea >or= 7 mmol/L, respiratory rate >or= 30 breaths/min, BP < 90 mm Hg systolic or < 60 mm Hg diastolic, age >or= 65 years (CURB-65). The primary outcome was 30-day mortality. RESULTS: A total of 1,653 patients formed the study cohort. MR-proADM levels consistently rose with PSI class and 30-day mortality (p < 0.001). MR-proADM had a higher area under the curve for 30-day mortality than procalcitonin (0.76 vs 0.65, respectively; p < 0.001), but adding MR-proADM to the PSI in all subjects minimally improved performance. Among low-risk subjects (PSI classes I to III), mortality was low and did not differ by MR-proADM quartile. However, among high-risk subjects (PSI class IV/V; n = 546), subjects in the highest MR-proADM quartile (n = 232; 42%) had higher 30-day mortality than those in MR-proADM quartiles 1 to 3 (23% vs 9%, respectively; p < 0.0001). Similar results were seen with CURB-65. MR-proADM and procalcitonin levels were generally concordant; only 6% of PSI class IV/V subjects in the highest MR-proADM quartile had very low procalcitonin levels (< 0.1 ng/mL). CONCLUSIONS: In our multicenter CAP cohort, MR-proADM levels correlate with increasing severity of illness and death. High MR-proADM levels offer additional risk stratification in high-risk CAP patients, but otherwise MR-proADM levels do not alter PSI-based risk assessment in most CAP patients.
BACKGROUND: Midregional proadrenomedullin (MR-proADM) is a potential prognostic biomarker in patients with community-acquired pneumonia (CAP). Previous work has been hampered by sample size and illness spectrum limits. We sought to describe the pattern of MR-proADM in a broad CAP cohort, confirm its prognostic role, and compare its performance to procalcitonin, a novel biomarker of infection. METHODS: We conducted a multicenter prospective cohort study in 28 community and teaching EDs. Patients with a clinical and radiographic diagnosis of CAP were enrolled. We stratified MR-proADM levels a priori into quartiles and quantified severity of illness using the pneumonia severity index (PSI); and confusion (abbreviated mental test score of <or= 8), urea >or= 7 mmol/L, respiratory rate >or= 30 breaths/min, BP < 90 mm Hg systolic or < 60 mm Hg diastolic, age >or= 65 years (CURB-65). The primary outcome was 30-day mortality. RESULTS: A total of 1,653 patients formed the study cohort. MR-proADM levels consistently rose with PSI class and 30-day mortality (p < 0.001). MR-proADM had a higher area under the curve for 30-day mortality than procalcitonin (0.76 vs 0.65, respectively; p < 0.001), but adding MR-proADM to the PSI in all subjects minimally improved performance. Among low-risk subjects (PSI classes I to III), mortality was low and did not differ by MR-proADM quartile. However, among high-risk subjects (PSI class IV/V; n = 546), subjects in the highest MR-proADM quartile (n = 232; 42%) had higher 30-day mortality than those in MR-proADM quartiles 1 to 3 (23% vs 9%, respectively; p < 0.0001). Similar results were seen with CURB-65. MR-proADM and procalcitonin levels were generally concordant; only 6% of PSI class IV/V subjects in the highest MR-proADM quartile had very low procalcitonin levels (< 0.1 ng/mL). CONCLUSIONS: In our multicenter CAP cohort, MR-proADM levels correlate with increasing severity of illness and death. High MR-proADM levels offer additional risk stratification in high-risk CAP patients, but otherwise MR-proADM levels do not alter PSI-based risk assessment in most CAP patients.
Authors: M S Niederman; L A Mandell; A Anzueto; J B Bass; W A Broughton; G D Campbell; N Dean; T File; M J Fine; P A Gross; F Martinez; T J Marrie; J F Plouffe; J Ramirez; G A Sarosi; A Torres; R Wilson; V L Yu Journal: Am J Respir Crit Care Med Date: 2001-06 Impact factor: 21.405
Authors: S S Richter; S E Beekmann; J L Croco; D J Diekema; F P Koontz; M A Pfaller; G V Doern Journal: J Clin Microbiol Date: 2002-07 Impact factor: 5.948
Authors: W S Lim; M M van der Eerden; R Laing; W G Boersma; N Karalus; G I Town; S A Lewis; J T Macfarlane Journal: Thorax Date: 2003-05 Impact factor: 9.139
Authors: T Shindo; H Kurihara; K Maemura; Y Kurihara; T Kuwaki; T Izumida; N Minamino; K H Ju; H Morita; Y Oh-hashi; M Kumada; K Kangawa; R Nagai; Y Yazaki Journal: Circulation Date: 2000-05-16 Impact factor: 29.690
Authors: Daiana Stolz; Mirjam Christ-Crain; Nils G Morgenthaler; David Miedinger; Jörg Leuppi; Christian Müller; Roland Bingisser; Joachim Struck; Beat Müller; Michael Tamm Journal: Chest Date: 2008-05-19 Impact factor: 9.410
Authors: M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij Journal: Clin Microbiol Infect Date: 2011-11 Impact factor: 8.067
Authors: Marta Di Pasquale; Mariano Esperatti; Ernesto Crisafulli; Miquel Ferrer; Gianluigi Li Bassi; Mariano Rinaudo; Angels Escorsell; Javier Fernandez; Antoni Mas; Francesco Blasi; Antoni Torres Journal: Intensive Care Med Date: 2013-08-02 Impact factor: 17.440
Authors: P P España; A Capelastegui; A Bilbao; R Diez; F Izquierdo; M J Lopez de Goicoetxea; J Gamazo; F Medel; J Salgado; I Gorostiaga; J M Quintana Journal: Eur J Clin Microbiol Infect Dis Date: 2012-08-05 Impact factor: 3.267